journal
MENU ▼
Read by QxMD icon Read
search

Journal of Comparative Effectiveness Research

journal
https://www.readbyqxmd.com/read/28884585/analysis-of-the-cost-effectiveness-of-carbetocin-for-the-prevention-of-hemorrhage-following-cesarean-delivery-in-ecuador
#1
Aquiles Rodrigo Henríquez-Trujillo, Ruth Alicia Lucio-Romero, Kerlly Bermúdez-Gallegos
AIM: To compare the cost of carbetocin with that of oxytocin for the prevention and management of hemorrhage following cesarean delivery in Ecuador. MATERIALS & METHODS: We developed a decision tree based cost-effectiveness model to compare carbetocin with oxytocin in the prevention of hemorrhage following cesarean delivery in Ecuador. Our model was run from a third party payer perspective and was validated by local experts in the field. The efficacy of the interventions was determined based on a systematic review of the literature...
September 8, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28857631/practical-implications-of-using-real-world-evidence-rwe-in-comparative-effectiveness-research-learnings-from-imi-getreal
#2
Amr Makady, Heather Stegenga, Antonio Ciaglia, Thomas Pa Debray, Michael Lees, Michael Happich, Bettina Ryll, Keith Abrams, Rob Thwaites, Sarah Garner, Páll Jonsson, Wim Goettsch
In light of increasing attention towards the use of real-world evidence (RWE) in decision making in recent years, this commentary aims to reflect on the experiences gained in accessing and using RWE for comparative effectiveness research as a part of the Innovative Medicines Initiative GetReal Consortium and discuss their implications for RWE use in decision-making.
August 31, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28840753/comparative-effectiveness-of-indacaterol-glycopyrronium-in-the-treatment-of-chronic-obstructive-pulmonary-disease
#3
Mario Cazzola, Paola Rogliani
Indacaterol/glycopyrronium has been the first long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed dose combination to be approved as a maintenance treatment in chronic obstructive pulmonary disease patients. Comparative effectiveness studies indicate that it is constantly superior to a LAMA or a LABA alone or even a LABA/inhaled corticosteroid combination, regardless of the drugs used. However, definitive data documenting the benefit of indacaterol/glycopyrronium fixed dose combination over these consolidated therapies are still absent in real-world, although the results of pivotal randomized controlled trials show that this is the case...
August 25, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28814107/real-world-comparison-of-treatment-patterns-and-effectiveness-of-albiglutide-and-liraglutide
#4
Erin K Buysman, Mirko V Sikirica, Sarah W Thayer, Michael Bogart, Mary C DuCharme, Ashish V Joshi
AIM: To compare medication adherence, discontinuation and glycemic control in patients receiving albiglutide versus liraglutide. PATIENTS & METHODS: Administrative claims data and glycated hemoglobin (HbA1c) results were analyzed from a sample of adult health plan members with Type 2 diabetes. RESULTS: Patients were matched 1:1 in the albiglutide (n = 2213) and liraglutide (n = 2213) overall cohorts and in 244 patients with HbA1c results from each treatment group...
August 17, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28809128/real-world-adherence-and-economic-outcomes-associated-with-paliperidone-palmitate-versus-oral-atypical-antipsychotics-in-schizophrenia-patients-with-substance-related-disorders-using-medicaid-benefits
#5
Kruti Joshi, Marie-Hélène Lafeuille, Rhiannon Kamstra, Sean Tiggelaar, Patrick Lefebvre, Edward Kim, Yong Yue, Neeta Tandon
AIM: Compare medication utilization, costs and healthcare resource use in schizophrenia patients with substance-related disorders initiated on once-monthly paliperidone palmitate (PP1M) or an oral atypical antipsychotic (OAA). MATERIALS & METHODS: Data from six Medicaid states (07/2009-03/2015) were used to compare outcomes between PP1M and OAA patients. RESULTS: PP1M patients had higher 12-month antipsychotic adherence and persistence than OAA patients...
August 15, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28805448/stakeholders-views-on-data-sharing-in-multicenter-studies
#6
Kathleen M Mazor, Allison Richards, Mia Gallagher, David E Arterburn, Marsha A Raebel, W Benjamin Nowell, Jeffrey R Curtis, Andrea R Paolino, Sengwee Toh
AIM: To understand stakeholders' views on data sharing in multicenter comparative effectiveness research studies and the value of privacy-protecting methods. MATERIALS & METHODS: Semistructured interviews with five US stakeholder groups. RESULTS: We completed 11 interviews, involving patients (n = 15), researchers (n = 10), Institutional Review Board and regulatory staff (n = 3), multicenter research governance experts (n = 2) and healthcare system leaders (n = 4)...
August 14, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28791875/incidence-of-dose-escalation-and-impact-on-biologic-costs-among-patients-with-rheumatoid-arthritis-treated-with-three-intravenous-agents
#7
Anagha Nadkarni, Donna McMorrow, Chad Patel, Robert Fowler, David Smith
AIM: Evaluation of dose escalation and costs among rheumatoid arthritis patients treated with intravenous abatacept, intravenous infliximab or intravenous tocilizumab. MATERIALS & METHODS: Adults with rheumatoid arthritis and biologic treatment were identified from the MarketScan(®) Research databases. Study outcomes included dose escalation, per-patient per-month (PPPM) biologic costs and PPPM all-cause total healthcare costs. Impact of dose escalation on biologic costs was estimated using multivariate analyses...
August 9, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28791873/comparing-biologic-persistence-and-healthcare-costs-in-rheumatoid-arthritis-patients-initiating-subcutaneous-biologics
#8
Anagha Nadkarni, Donna McMorrow, Robert Fowler, David Smith
AIM: Comparing biologic persistence and healthcare costs between rheumatoid arthritis (RA) patients initiating first- or second-line subcutaneous abatacept, adalimumab, or etanercept. MATERIALS & METHODS: Retrospective, observational cohort study, which included adults with RA who initiated either of the three treatments between 29 July 2011 and 1 July 2015. Total healthcare costs were measured during baseline and follow-up. Biologic persistence was compared using multivariable Cox proportional hazards regression...
August 9, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28766976/phedra-using-real-world-data-to-analyze-treatment-patterns-and-ibrutinib-effectiveness-in-hematological-malignancies
#9
Jamie Garside, Nollaig Healy, Hervé Besson, Ruben Hermans, Finlay MacDougall, Damien Lestelle, Joris Diels, Wafae Iraqi
AIM: PHEDRA (Platform for Haematology in EMEA: Data for Real World Analysis) is a unique, noninterventional project based on secondary data collection from real-world (RW) patient-level (health record) databases to understand treatment patterns in hematological malignancies. It compares ibrutinib's effectiveness with alternative treatments using RW data (RWD) and randomized clinical trials data. MATERIALS & METHODS: RWD are cleaned, validated, harmonized into a Common Data Model, and analyzed statistically alongside randomized clinical trial data...
August 2, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28737102/comparative-effectiveness-of-rivaroxaban-in-the-treatment-of-nonvalvular-atrial-fibrillation
#10
Faye L Norby, Alvaro Alonso
Rivaroxaban is a direct oral anticoagulant (DOAC) approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, a common arrhythmia. In this review, we summarize the effectiveness of rivaroxaban versus warfarin and the DOACs dabigatran, apixaban and edoxaban. The primary focus is on primary evidence from clinical trials, indirect comparison studies and real-world studies. While there are gaps in the literature, the evidence thus far indicates that rivaroxaban is superior to warfarin and similar to dabigatran, apixaban and edoxaban for the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation, although rivaroxaban may be associated with an elevated bleeding risk compared with other DOACs...
July 24, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28699780/depression-anxiety-and-stress-severities-in-multiple-sclerosis-patients-using-injectable-versus-oral-treatments
#11
Fawaz Al-Hussain, Noura Al-Salloum, Naael Alazwary, Jameelah Saeedi, Sara Howaidi, Abdulkader Daif
AIM: Studies on multiple sclerosis in Saudi Arabia remain scant, particularly studies on the psychological aspects. This study measures severities of depression, anxiety and stress, and compares them to the used disease-modifying treatment. MATERIALS & METHODS: Cross-sectional study using a phone questionnaire targeting 452 Saudi patients with relapsing-remitting multiple sclerosis following in King Khalid University Hospital, King Fahad Medical City or Security Forces Hospital...
July 12, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28699779/indication-specific-pricing-of-pharmaceuticals-in-the-us-healthcare-system
#12
Steven D Pearson, William B Dreitlein, Chris Henshall, Adrian Towse
AIM: To explore the potential of indication-specific pricing (ISP) of pharmaceuticals and to discuss prospects for implementation in the US healthcare system. MATERIALS & METHODS: The Institute for Clinical and Economic Review convened a policy forum with 44 healthcare leaders from 22 payer and life sciences companies. Models of ISP were discussed. RESULTS: Payers and drug manufacturers saw the potential benefits of an ISP system that balances affordability for payers, sustainability for manufacturers and access for patients...
July 12, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28699771/comparative-effectiveness-of-surgery-versus-antibiotics-in-acute-appendicitis-a-systematic-review
#13
Stephanie D Talutis, Frederick Thurston Drake
AIM: To review outcomes of surgical and antibiotic management of acute appendicitis. METHODS: 11 prospective studies comparing surgical versus antibiotic management of acute appendicitis over a 21-year period were reviewed. RESULTS: Antibiotic management is successful in most cases of uncomplicated acute appendicitis. The need for crossover in management and recurrent appendicitis were low among all studies. For those patients who ultimately required surgery, no increased complications were observed...
July 12, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28699769/deriving-more-value-from-rwe-to-ensure-timely-access-of-medicines-by-patients
#14
Sarah Wamala Andersson, Mattias Kyhlstedt
No abstract text is available yet for this article.
July 12, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28686060/show-me-the-money-an-analysis-of-underserved-stakeholders-funding-priorities-in-patient-centered-outcomes-research-domains
#15
Stephanie Solomon Cargill, Lauren Lyn Baker, Susan Dorr Goold
AIM: Develop an accessible exercise to engage underserved populations about research funding priorities; analyze the criteria they use to prioritize research; contrast these criteria to those currently used by Patient Centered Outcomes Research Institute (PCORI). MATERIALS & METHODS: Academic and community partners collaborated to develop an Ipad exercise to facilitate group deliberation about PCOR funding priorities. Sixteen groups (n = 183) of underserved individuals in both urban and rural areas participated...
July 7, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28686057/patient-relevant-outcomes-associated-with-generic-tamsulosin-levothyroxine-and-amphetamine-in-the-fda-adverse-event-reporting-system-a-pilot-study
#16
Sathiya Priya Marimuthu, Geetha Iyer, Jodi B Segal, Sonal Singh
AIM: Patient-reported outcomes associated with adverse events (AEs) reported with generics have not been evaluated. To map AEs associated with generics to the NIH Patient-reported Outcomes Measurement Information System. METHODS: We mapped 381 AEs from 148 case reports of generic tamsulosin, levothyroxine and amphetamine/dextroamphetamine to the physical, mental and social domain of the NIH Patient-Reported Outcomes Measurement Information System after reviewing 1237 case reports in the US FDA's Adverse Event Reporting System (FAERS; 2011-2013)...
July 7, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28686055/a-stakeholder-informed-randomized-controlled-comparative-effectiveness-study-of-an-order-prescribing-intervention-to-improve-colony-stimulating-factor-use-for-cancer-patients-receiving-myelosuppressive-chemotherapy-the-tracer-study
#17
Aasthaa Bansal, Sean D Sullivan, Dawn L Hershman, Gary H Lyman, William E Barlow, Jeannine S McCune, Scott D Ramsey
Colony stimulating factors (CSF) are widely prescribed to avoid febrile neutropenia (FN) among cancer patients receiving chemotherapy, but studies show their use is often not consistent with practice guidelines. In addition, there is limited high quality evidence assessing benefits and harms of primary prophylactic-CSF (PP-CSF) in the setting of chemotherapy that poses an intermediate risk of FN. To address these issues, with funding from the Patient Centered Outcomes Research Institute (PCORI) and the National Cancer Institute's Community Oncology Research Program, SWOG is sponsoring a prospective, cluster randomized controlled pragmatic trial of an automated order entry protocol for PP-CSF among patients with breast, lung and colorectal cancer receiving myelosuppressive chemotherapy, with a nested randomized controlled trial of PP-CSF for patients receiving intermediate risk chemotherapy...
July 7, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28660802/efficacy-and-safety-of-ustekinumab-in-the-induction-therapy-of-tnf-%C3%AE-refractory-crohn-s-disease-patients-a-systematic-review-and-meta-analysis
#18
Paweł Kawalec, Paweł Moćko, Iwona Malinowska-Lipien, Tomasz Brzostek
AIM: The aim of the systematic review and meta-analysis was to assess the efficacy and safety of ustekinumab in the induction therapy of anti-TNF-α failure patients with Crohn's disease. METHODS: A systematic literature search was conducted in Medline (PubMed), EMBASE, Cochrane Library until 30 December 2016. We included randomized controlled trials that compared efficacy (clinical response and remission) and safety profile of ustekinumab in TNF-α failure Crohn's disease patients; primary and secondary TNF-α nonresponders or intolerant patients were also assessed...
June 29, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28627930/randomized-comparative-efficacy-and-safety-study-of-intermittent-simvastatin-versus-fenofibrate-in-hemodialysis
#19
Aya M Abdel Magid, Maggie M Abbassi, Essam Eldin M Iskander, Osama Mohamady, Samar F Farid
AIM: Compare the safety and efficacy of intermittent fenofibrate versus simvastatin in chronic hemodialysis patients. PATIENTS & METHODS: Sixty patients received either fenofibrate 100 mg or simvastatin 20 mg after their dialysis session (parallel study). The safety and efficacy of drugs on lipid profile, oxidized low-density lipoprotein (Ox-LDL), glutathione peroxidase and C-reactive protein were compared before and after 16-week treatment. RESULTS: After treatment, significant increase in glutathione peroxidase, significant decrease in total cholesterol, triglycerides, low density lipoprotein (LDL) and ox-LDL (p < 0...
June 19, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28621558/patient-engagement-in-patient-centered-outcomes-research-challenges-facilitators-and-actions-to-strengthen-the-field
#20
Lauren E Ellis, Nancy E Kass
AIM: To describe challenges to and facilitators of patient engagement to inform future strategies and suggested actions to strengthen engagement. METHODS: Interviews with 19 principal investigators of projects funded by the Patient-Centered Outcomes Research Institute and with 33 patients from 18 of the 19 projects. RESULTS: Facilitators included using existing resources, having clear goals, educating patients and treating patients respectfully...
June 16, 2017: Journal of Comparative Effectiveness Research
journal
journal
43925
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"